Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Research Letter
You have accessRestricted Access

Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD

Tessa K. Novick, Aditya Surapaneni, Jung-Im Shin, Shoshana H. Ballew, G. Caleb Alexander, Lesley A. Inker, Alex R. Chang and Morgan E. Grams
CJASN December 2018, 13 (12) 1886-1888; DOI: https://doi.org/10.2215/CJN.08530718
Tessa K. Novick
1Division of Nephrology, Department of Internal Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aditya Surapaneni
2Welch Center for Prevention, Epidemiology and Clinical Research, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jung-Im Shin
2Welch Center for Prevention, Epidemiology and Clinical Research, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoshana H. Ballew
2Welch Center for Prevention, Epidemiology and Clinical Research, and
3Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Caleb Alexander
3Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lesley A. Inker
4Division of Nephrology, Department of Internal Medicine, Tufts Medical Center, Boston, Massachusetts; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex R. Chang
5Division of Nephrology, Geisinger Health System, Danville, Pennsylvania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Morgan E. Grams
1Division of Nephrology, Department of Internal Medicine,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • chronic kidney disease
  • pain medications
  • chronic pain
  • Prevalence
  • Analgesics
  • Opioid
  • Anti-Inflammatory Agents, Non-Steroidal
  • Renal Insufficiency, Chronic

Over 60% of individuals with CKD have chronic pain, a prevalence two to three times that of the general population (1). Although the pharmacologic treatment of pain among individuals with normal kidney function is often challenging, pain management in people with CKD is even more complicated (1). Nonsteroidal anti-inflammatory drugs (NSAIDs) may be contraindicated in those with CKD (1). Although opioids may lack the direct nephrotoxicity of NSAIDs, nearly all undergo at least partial excretion by the kidneys (2). Gabapentinoids (gabapentin and pregabalin) are alternative therapeutic options, but they also rely primarily on excretion through the kidneys (3,4). Little is known regarding the prevalence of prescription opioid use among patients with CKD; how this compares with other analgesics, such as gabapentinoids and NSAIDs; and how prevalence compares with that in individuals with normal kidney function.

We assessed the prevalence of prescriptions for opioids (including tramadol, methadone and buprenorphine), gabapentinoids, and NSAIDs (excluding aspirin and topical formulations) across stages of kidney function in primary care patients using the Geisinger Health System, a large rural health system in Pennsylvania, and Johns Hopkins Medicine, a large health system in Maryland. We chose two populations to explicitly evaluate geographic differences in prescribing patterns and CKD prevalence (5). We included all patients over age 18 years old with at least one outpatient measure of serum creatinine between 2011 and 2016 at Geisinger and between 2013 and 2016 at Johns Hopkins Medicine. The study was deemed exempt by the Geisinger Medical Center Institutional Review Board and the Johns Hopkins University School of Medicine.

A period prevalence cohort was created for each calendar year in Geisinger and Johns Hopkins Medicine including all eligible individuals with at least one outpatient creatinine measure. We defined opioid, gabapentinoid, and NSAID use as electronic medical record documentation of at least one outpatient prescription or patient self-report at any point during the calendar year. We used the first annual outpatient serum creatinine value and the Chronic Kidney Disease Epidemiology Collaboration equation to calculate eGFR (6). Individuals were categorized into CKD stages according to the Kidney Disease Improving Global Outcomes (KDIGO) guideline (7). We calculated the proportion of individuals who received at least one opioid, gabapentinoid, or NSAID prescription within each CKD stage between January 1 and December 31. Prevalence ratios were estimated adjusting for age, sex, and race. All analyses were performed using Stata version 14.2 (StataCorp, College Station, TX).

In total, 333,049 patients had at least one serum creatinine measured between 2011 and 2016 in the Geisinger cohort, and 188,403 patients had at least one serum creatinine measured between 2013 and 2016 in the Johns Hopkins Medicine cohort. In 2016, there were 181,107 and 109,219 patients in Geisinger and Johns Hopkins Medicine, respectively, and 31.8% and 22.7% received at least one prescription for an opioid, respectively (Table 1). Adjusting for demographics, patients with CKD stage G4/G5 were 40% more likely than those with CKD stage G1 to receive an opioid prescription in Geisinger and 90% more likely to receive a prescription in Johns Hopkins Medicine. Among those with CKD stage G4/G5, crude prevalence increased over time in both Geisinger and Johns Hopkins Medicine cohorts (P<0.001).

View this table:
  • View inline
  • View popup
Table 1.

Population characteristics and crude and adjusted prevalence and prevalence ratios of opioid, gabapentinoid, and nonsteroidal anti-inflammatory drug prescriptions at Geisinger Health System and Johns Hopkins Medicine in 2016

Gabapentin and pregabalin prescriptions were less common in the overall cohort: at 9.9% and 6.3% of the Geisinger and Johns Hopkins Medicine cohorts in 2016, respectively. Similar to opioid prescriptions, gabapentinoids were more common among patients with lower eGFR, and prescriptions among patients with stage G4/G5 CKD in particular increased over time.

Overall, NSAID use was similar across the two cohorts. In contrast to opioids and gabapentinoids, NSAID use was lower in patients with lower eGFR in both cohorts. Trends in NSAID use over time were more variable.

Several limitations bear mention. The study describes medication use in two large cohorts, and it was not designed to make therapeutic recommendations by level of eGFR or investigate whether pain medications cause CKD. Medication exposure was determined using electronic medical records, and it may not be a true reflection of use. We may have missed over-the-counter NSAID use and prescriptions from providers outside the Geisinger and Johns Hopkins Medicine systems. We only adjusted for demographic variables without taking into account pain chronicity, severity, or etiology, and the relationship between increased prescriptions at lower eGFR may reflect a higher burden of comorbidities. Creatinine measurement and prescription were not necessarily concomitant. Finally, prescription trends over time were assessed in period prevalent cohorts, with overlap in the study population from year to year.

Using real world clinical data from two large tertiary health care systems, we report that prescriptions for opioids and gabapentinoids were common in patients with advanced CKD. Differences between the two cohorts may reflect the geographic variability in opioid prescriptions across the United States (5). Our findings highlight the need for heightened awareness regarding opioid and gabapentinoid use in the CKD population as well as additional studies to determine the safety of such medications in clinical practice.

Disclosures

G.C.A. is Chair of the Food and Drug Administration’s Peripheral and Central Nervous System Advisory Committee; serves as a paid advisor to IQVIA; serves on the advisory board of MesaRx Innovations; holds equity in Monument Analytics, a health care consultancy with clients that include the life sciences industry as well as plaintiffs in opioid litigation; and is a member of OptumRx’s National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.

Acknowledgments

Research reported in this publication was supported by grants R01 DK115534 (principal investigators: L.A.I. and M.E.G.) and R01 DK100446 (principal investigators: M.E.G. and Dr. Coresh) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. T.K.N. was supported by training grant T32 DK007732 24 from the NIDDK.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2018 by the American Society of Nephrology

References

  1. ↵
    1. Davison SN
    : Pain, analgesics, and safety in patients with CKD. Clin J Am Soc Nephrol 10: 350–352, 2015
    OpenUrlFREE Full Text
  2. ↵
    1. Smith HS
    : The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain 27: 824–838, 2011pmid:21677572
    OpenUrlCrossRefPubMed
  3. ↵
    1. Vollmer KO,
    2. von Hodenberg A,
    3. Kölle EU
    : Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 36: 830–839, 1986pmid:3730018
    OpenUrlPubMed
  4. ↵
    Parke-Davis (per FDA): Product Information: LYRICA(R) CR Oral Extended-Release Tablets, Pregabalin Oral Extended-Release Tablets, New York, Parke-Davis, 2017
  5. ↵
    1. Schuchat A,
    2. Houry D,
    3. Guy GP Jr.
    .: New data on opioid use and prescribing in the United States. JAMA 318: 425–426, 2017pmid:28687823
    OpenUrlPubMed
  6. ↵
    1. Levey AS,
    2. Stevens LA,
    3. Schmid CH,
    4. Zhang YL,
    5. Castro AF 3rd.,
    6. Feldman HI,
    7. Kusek JW,
    8. Eggers P,
    9. Van Lente F,
    10. Greene T,
    11. Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
    : A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009pmid:19414839
    OpenUrlCrossRefPubMed
  7. ↵
    1. Levin A,
    2. Stevens PE,
    3. Bilous RW,
    4. Coresh J,
    5. De Francisco ALM,
    6. De Jong PE,
    7. Griffith KE,
    8. Hemmelgarn BR,
    9. Iseki K,
    10. Lamb EJ,
    11. Levey AS,
    12. Riella MC,
    13. Shlipak MG,
    14. Wang H,
    15. White CT,
    16. Winearls CG; Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
    : KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 3: 1–150, 2013
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 13 (12)
Clinical Journal of the American Society of Nephrology
Vol. 13, Issue 12
December 07, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD
Tessa K. Novick, Aditya Surapaneni, Jung-Im Shin, Shoshana H. Ballew, G. Caleb Alexander, Lesley A. Inker, Alex R. Chang, Morgan E. Grams
CJASN Dec 2018, 13 (12) 1886-1888; DOI: 10.2215/CJN.08530718

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Prevalence of Opioid, Gabapentinoid, and NSAID Use in Patients with CKD
Tessa K. Novick, Aditya Surapaneni, Jung-Im Shin, Shoshana H. Ballew, G. Caleb Alexander, Lesley A. Inker, Alex R. Chang, Morgan E. Grams
CJASN Dec 2018, 13 (12) 1886-1888; DOI: 10.2215/CJN.08530718
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • A Comparison of Different Estimates of Albuminuria in Association with Mortality in Epidemiologic Research
  • QT Interval in Adult with Chronic Hypokalemia due to Gitelman Syndrome
  • COVID-19 in Children with Nephrotic Syndrome on Anti-CD20 Chronic Immunosuppression
Show more Research Letter

Cited By...

  • Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: PRO
  • Associations of Opioid Prescriptions with Death and Hospitalization across the Spectrum of Estimated GFR
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • chronic kidney disease
  • pain medications
  • chronic pain
  • prevalence
  • Analgesics
  • Opioid
  • Anti-Inflammatory Agents, Non-Steroidal
  • Renal Insufficiency, Chronic

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire